Navigation Links
Amarantus BioSciences Issues CEO Letter to Shareholders
Date:11/19/2012

from thought-leaders and have offset some of the financial burden of running proof-of-concept studies. The Company has already taken steps to improve our prospects in future partnering discussions from a corporate structure standpoint, and we will continue to improve MANF's prospects by focusing on further differentiating MANF from its competition, especially in Parkinson's disease. To further this objective, we have added certain key advisors to assist management in preparing a winning strategy to obtain the most value from our MANF program. With these new additions, we have gained access to significant intellectual capital, as well as invaluable insight into the realm of preparing both our asset and our corporation for successful partnerships.

MANF's current lead indication is Parkinson's disease, an area where we have produced very promising results. We have also achieved positive data in Traumatic Brain Injury (TBI) through our collaboration with Banyan Biomarkers. Our #C4CT program has attracted significant attention among NFL players and other professional athletes who have suffered from brain injuries, and we intend to leverage those relationships to raise awareness of MANF's potential role in TBI. In addition to Parkinson's disease and TBI, MANF has shown to be effective across a broad range of indications. The recent publication of myocardial infarction data validating a MANF-based approach has added significant value to our patent portfolio. Myocardial Infarction is a $5B market where there are currently no approved drugs to address the ischemia and reperfusion related injuries associated with heart attacks.

Perhaps most interesting from a time-to-market standpoint, is the emerging evidence that MANF has activity in certain rare and ultra-rare orphan diseases. The orphan drug strategy that management is pursuing will seek a path to commercialize MANF as expeditiously and cost-effectively as possible, and potentially
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amarantus BioSciences Secures $1.1 Million in Financing
2. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
3. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
6. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
7. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
8. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
10. Neurocrine Biosciences Reports Third Quarter 2012 Results
11. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... AxioMx Inc. , a ... Institutes of Health (NIH) has awarded the company a Phase I Small Business ... Institute of Diabetes and Digestive and Kidney Diseases. AxioMx will use this award ...
(Date:9/1/2015)... ... 01, 2015 , ... Knowledgent , the data and analytics firm, today ... utilizing data lakes in the healthcare industry. , As the Internet of Things (IoT) ... over the last few years as more entities become technology enabled through Electronic Medical ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... colleagues from University of California Los Angeles, Boston University School of Medicine, Frederick ... appears in PLOS One, the world’s first multidisciplinary Open Access journal. , ...
(Date:8/31/2015)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... for air emission abatement projects in North America ... order for a municipality in the Southern USA ... system that failed to meet the customer,s requirements. This demonstrates the ... Derek S. Webb , President and Chief Executive Officer.  ...
Breaking Biology Technology:AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3
... The state will give $250,000 in tax credits to C3 ... an 18,000-square-foot facility in Appleton's Northeast Business Park. , ,According ... create 28 jobs in the area. The credits are part ... aside $5 million in tax credits for each of eight ...
... up with UW-Eau Claire, UW-Stout and several other tech ... in the state. , ,Nanotechnology deals with particles one ... physical properties of matter begin to give way to ... understand. The potential of arranging nanoparticles, which scientists long ...
... the University of Wisconsin-Madison are taking another look at some ... That's what scientists call the way sounds change as you ... example, a jackhammer or a siren will sound higher pitched ... ,But there's an inverse Doppler effect, too, predicted ...
Cached Biology Technology:Chippewa Valley Technical College helps pioneer nanotech program, incubator 2Chippewa Valley Technical College helps pioneer nanotech program, incubator 3Chippewa Valley Technical College helps pioneer nanotech program, incubator 4
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... new sales campaign for Q4 2015. The new marketing ... team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) ... Group is a leader in retail driven marketing and ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Rep. Honda to Visit Crossmatch in Redwood City 2
... when the Food and Drug Administration is reconsidering the ... study offers further evidence to support a University of ... treatment may be in order. Richard ... Houston College of Pharmacy (UHCOP), has been investigating whether ...
... Ill. -- Most people know that too much sodium from ... that people trying to lower their blood pressure should also ... to sodium. Researchers found that the ratio of sodium-to-potassium ... disease than sodium or potassium alone. "There isn,t ...
... the first clinical evidence that gene therapy reduces symptoms ... this promising treatment which has endured a sometimes turbulent ... Human Gene Therapy the findings stem from ... conducted in Germany and led by an investigator at ...
Cached Biology News:New asthma research opposes current drug treatment, says UH prof 2New asthma research opposes current drug treatment, says UH prof 3New asthma research opposes current drug treatment, says UH prof 4Cutting salt isn't the only way to reduce blood pressure 2Gene therapy demonstrates benefit in patients with rheumatoid arthritis 2Gene therapy demonstrates benefit in patients with rheumatoid arthritis 3
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human OSCAR MAb (Clone 259501)...
Human/Mouse G9a/EHMT2 MAb (Clone A8620A) Keywords: Eu-HMTase2...
Human M-CSF...
Biology Products: